Can you specify the new chemical components in apotex's ruxolitinib formulation?

I can help, but I need one key detail first: which exact Apotex product are you referring to (e.g., brand + strength, and ideally the market/country), because the excipient list can differ by jurisdiction and by formulation revision.

Also, when you say “new chemical components,” do you mean:

1. new excipients (inactive ingredients) compared with a previous version, or
2. new API salt/polymorph/manufacturing-related components, or
3. you’re asking about what changed after an update (e.g., due to reformulation)?

What I can do once you confirm

• Extract the full current excipient list from the specific Apotex package insert / SmPC you mean.
• Identify which components are new relative to the prior version you provide (or relative to another document you name).
• If you paste the two excipient tables, I can compute the exact differences.

Please reply with

• Product name (e.g., “Ruxolitinib Tablets ___ mg”), and
• Country/agency (FDA/Health Canada/EMA/etc.),
• Strength(s), and
• Either:
  • a link or text from the current label/SmPC, and the previous one you’re comparing to, or
  • upload/paste both excipient lists.

Once I have that, I’ll specify exactly what the “new chemical components” are.